Price $13.71
Year Range $3.96 - $13.71
Target Price Sign up
Volume 607,160
Market Cap $884M
Dividend Yield 0%
Industry Medical Devices

Webpage Traffic View All


Job Posts View All


Business Outlook View All


Bioventus - AI Stock Analysis

Analysis generated November 4, 2024

Bioventus is a company focused on developing and commercializing clinically proven and minimally invasive treatments that engage and enhance the body’s natural healing process. With products and services that integrate into the continuum of orthopedic care—from surgical to non-surgical solutions—the company represents an important player in the medical device industry.

Fundamental Analysis

In the last quarter, Bioventus recorded a revenue of $151 million. This is an increase of 17.35% compared to the previous quarter, signaling strong short-term growth. Comparing this to the same quarter last year, there is an 11.30% increase, indicating positive year-over-year growth. These numbers are crucial as they reflect the company's ability to continuously increase its revenue.

However, the net income for the last quarter was reported at $24 million, representing a significant decrease of 424.99% compared to the previous quarter and a decrease of 551.78% compared to the same quarter last year. Such drastic declines in net income are red flags and may point to financial instability or operational inefficiencies that need to be addressed.

EBITDA for the last quarter stood at $27 million—a drop of 1,518.49% compared to the previous quarter, and a staggering 3,414.03% decrease compared to the same quarter last year. These numbers warrant serious concern and suggest that despite revenue growth, the company’s cost structure or other expenses are negatively impacting profitability.

Technical Analysis

As of today, the stock price of Bioventus is $13.78, an increase of 17.28% compared to a month ago, showing a positive short-term trend. On a longer timeline, the stock price has surged by 258.85% over the past year, which suggests robust market confidence and sustained bullish sentiment toward the company's prospects.

The current Simple Moving Average (SMA10) is $13.45, slightly higher than the previous SMA10 of $13.39. This marginal increase indicates a potential upward trend in price movement. Additionally, the Relative Strength Index (RSI) stands at 49.6, depicting a neutral condition. This indicates that the stock isn't overbought or oversold, thus presenting a balanced outlook from a technical perspective.

Alternative Data Analysis

Looking at alternative data, Bioventus has 32 open job positions, a decline of 6% over the last couple of months. This drop suggests potential cost-cutting or margin-improvement efforts, not a positive indicator for a growing company. The business outlook among employees is neutral, reflecting neither optimism nor pessimism.

In terms of customer acquisition, Bioventus has seen an estimated 14,000 visitors to its webpage, up by 100% in recent months. This is a bullish sign indicating growing interest and potential customer base expansion. However, customer engagement on social media remains static with 640 followers on Instagram and 1,900 followers on Twitter, with no meaningful changes.

Lastly, according to AltIndex’s AI score of 46, Bioventus falls into the 'hold' category. This score takes into account various fundamental, technical, and alternative data, providing a hybrid outlook consolidating multiple facets of the company’s performance and prospects.

Conclusion and Recommendation

Bioventus presents a mixed yet intriguing investment case. The company’s revenue growth is promising, but drastic declines in net income and EBITDA are areas of concern that need serious attention. Technically, the stock has exhibited strong performance both in the short and long term, suggesting market confidence in its future. Alternative data paints a neutral picture with some positive indicators in web traffic growth but tempered by a lack of social media engagement and declining job postings.

Given all these factors, a cautious approach would be advisable. The recommendation is to hold the stock while closely monitoring the company’s financial performance over the next few quarters to see if it can stabilize its profitability issues. Positive developments in net income and EBITDA would be essential triggers for a stronger buying recommendation.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.